Results 81 to 90 of about 740 (167)

Multiple Genomic Alterations, Including a Novel AFF4::IRF1 Fusion Gene, in a Treatment-Refractory Blastic Plasmacytoid Dendritic-Cell Neoplasm: A Case Report and Literature Review

, 2023
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy with an aggressive clinical course and poor prognosis. The genetic abnormalities in BPDCN are heterogeneous; therefore, its molecular pathogenesis and the prognostic ...
Jianming Pei, Reza Nejati, Joseph R. Testa, Nashwa Mansoor, Michael Styler, Y. Lynn Wang, Yavuz Sahin   +6 more
core   +1 more source

NEOPLASIA DE CÉLULAS DENDRÍTICAS PLASMOCITÓIDES COMO DIAGNÓSTICO DIFERENCIAL DE LESÕES CUTÂNEAS EM PACIENTES PEDIÁTRICOS

Hematology, Transfusion and Cell Therapy
Objetivos: Descrever a experiência e desafio diagnóstico de dois pacientes pediátricos com neoplasia de células dendríticas plasmocitóides com apresentação clínica de lesões cutâneas.
GPG Spohr, GM Altizani, AKF Costa, ET Valera, ALM Leite, DP Leal, MBF Reis   +6 more
doaj   +1 more source

Allogeneic hematopoietic cell transplantation as the standard of care for blastic plasmacytoid dendritic cell neoplasm in first complete remission

Hematology/Oncology and Stem Cell Therapy
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic disorder derived from precursors of plasmacytoid dendritic cells, with a generally aggressive clinical course.
Mohamed A. Kharfan-Dabaja
doaj   +1 more source

Central nervous system management remains an evidence gap in first-line tagraxofusp therapy for blastic plasmacytoid dendritic cell neoplasm. Comment on: “First-line tagraxofusp leads to durable responses and prolonged survival in adults with blastic plasmacytoid dendritic cell neoplasm regardless of fitness level”

Haematologica
Not available.
Shigeru Kusumoto, Takayoshi Tachibana
doaj   +1 more source

Poster Sessions

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

Tagraxofusp in combination with pomalidomide and dexamethasone in relapsed and / or refractory multiple myeloma shows encouraging preliminary efficacy with a manageable safety profile

Haematologica
Not available.
Paul Richardson, Myo Htut, Emma Scott, Claudia Paba Prada, Ira Gupta   +4 more
doaj   +1 more source

Evaluation of targeted therapies for the management of hematological malignancies involving plasmocytoid dendritic cells

, 2022
Les hémopathies impliquant des pDC (BPDCN et LAM-pDC) sont des entités récemment décrites et présentant un pronostic défavorable. Elles sont rares et ne présentent actuellement aucun consensus de traitement.
Poussard, Margaux
core  

Assessing the risk of tumor lysis syndrome associated with the use of antineoplastic agents: a real-world pharmacovigilance study based on the FDA Adverse Event Reporting System database

Therapeutic Advances in Drug Safety
Background: The use of antineoplastic agents is one of the important triggers of tumor lysis syndrome (TLS), but there is still a lack of comprehensive understanding of antineoplastic agents that may trigger TLS and the TLS risk differences between ...
Dongxuan Li, Chunmeng Qin, Hongli Wang, Dan Du, Yalan Wang, Qian Du, Songqing Liu   +6 more
doaj   +1 more source

Phase 2 Multicenter Trial of Tagraxofusp in Combination with Venetoclax and Azacitidine in Adults with Previously Untreated CD123+ Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy

Background and Significance: Although complete remission (CR) rates after first-line therapy in acute myeloid leukemia (AML) are relatively high, some patients cannot tolerate high-intensity treatments or have a high risk of relapse with standard ...
Gupta, Ira, Pemmaraju, Naveen, Sekeres, Mikkael A., Lane, Andrew A., Kantarjian, Hagop M., Fathi, Amir T., Compagnoni, Anna, Garzon, Jessica, Tosolini, Alessandra, Daver, Naval   +9 more
core   +1 more source

NEOPLASIA DE CÉLULAS DENDRÍTICAS PLASMOCITOIDES BLÁSTICAS COM APRESENTAÇÃO LEUCÊMICA: UM RELATO DE CASO

Hematology, Transfusion and Cell Therapy
Introdução: A neoplasia de células dendríticas plasmocitoides blásticas (NCDPB) é um subtipo raro de malignidade de células dendríticas, correspondendo a cerca de 0,44% de todas as neoplasias hematológicas.
ACK Torrani, DH Catelli, FM Carlotto, JB Gazabon, MPMS Klauberg, RH Sassi, NH Dias, PA Guazzelli, MPB Malcon, AA Paz   +9 more
doaj   +1 more source